tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2356269.
doi: 10.1080/21645515.2024.2356269. Epub 2024 Jun 2. Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies
Hua Shi[SUP] 1 [/SUP], Xiaojian Zhang[SUP] 1 [/SUP], Pan Ge[SUP] 1 2 [/SUP], Victoria Meliopoulos[SUP] 3 [/SUP], Pam Freiden[SUP] 3 [/SUP], Brandi Livingston[SUP] 3 [/SUP], Stacey Schultz-Cherry[SUP] 3 [/SUP], Ted M Ross[SUP] 1 2 4 5 [/SUP]
Affiliations
The influenza viruses cause seasonal respiratory illness that affect millions of people globally every year. Prophylactic vaccines are the recommended method to prevent the breakout of influenza epidemics. One of the current commercial influenza vaccines consists of inactivated viruses that are selected months prior to the start of a new influenza season. In many seasons, the vaccine effectiveness (VE) of these vaccines can be relatively low. Therefore, there is an urgent need to develop an improved, more universal influenza vaccine (UIV) that can provide broad protection against various drifted strains in all age groups. To meet this need, the computationally optimized broadly reactive antigen (COBRA) methodology was developed to design a hemagglutinin (HA) molecule as a new influenza vaccine. In this study, COBRA HA-based inactivated influenza viruses (IIV) expressing the COBRA HA from H1 or H3 influenza viruses were developed and characterized for the elicitation of immediate and long-term protective immunity in both immunologically naïve or influenza pre-immune animal models. These results were compared to animals vaccinated with IIV vaccines expressing wild-type H1 or H3 HA proteins (WT-IIV). The COBRA-IIV elicited long-lasting broadly reactive antibodies that had hemagglutination-inhibition (HAI) activity against drifted influenza variants.
Keywords: COBRA; hemagglutinin; inactivated influenza vaccine; long-lasting antibody.
. 2024 Dec 31;20(1):2356269.
doi: 10.1080/21645515.2024.2356269. Epub 2024 Jun 2. Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies
Hua Shi[SUP] 1 [/SUP], Xiaojian Zhang[SUP] 1 [/SUP], Pan Ge[SUP] 1 2 [/SUP], Victoria Meliopoulos[SUP] 3 [/SUP], Pam Freiden[SUP] 3 [/SUP], Brandi Livingston[SUP] 3 [/SUP], Stacey Schultz-Cherry[SUP] 3 [/SUP], Ted M Ross[SUP] 1 2 4 5 [/SUP]
Affiliations
- PMID: 38826029
- DOI: 10.1080/21645515.2024.2356269
The influenza viruses cause seasonal respiratory illness that affect millions of people globally every year. Prophylactic vaccines are the recommended method to prevent the breakout of influenza epidemics. One of the current commercial influenza vaccines consists of inactivated viruses that are selected months prior to the start of a new influenza season. In many seasons, the vaccine effectiveness (VE) of these vaccines can be relatively low. Therefore, there is an urgent need to develop an improved, more universal influenza vaccine (UIV) that can provide broad protection against various drifted strains in all age groups. To meet this need, the computationally optimized broadly reactive antigen (COBRA) methodology was developed to design a hemagglutinin (HA) molecule as a new influenza vaccine. In this study, COBRA HA-based inactivated influenza viruses (IIV) expressing the COBRA HA from H1 or H3 influenza viruses were developed and characterized for the elicitation of immediate and long-term protective immunity in both immunologically naïve or influenza pre-immune animal models. These results were compared to animals vaccinated with IIV vaccines expressing wild-type H1 or H3 HA proteins (WT-IIV). The COBRA-IIV elicited long-lasting broadly reactive antibodies that had hemagglutination-inhibition (HAI) activity against drifted influenza variants.
Keywords: COBRA; hemagglutinin; inactivated influenza vaccine; long-lasting antibody.